[EXECUTION VERSION CHINA BIOLOGIC PRODUCTS, INC. UNDERWRITING AGREEMENT June 10, 2015 June 10, 2015 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, N.Y. 10010 Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, New York 10036 Jefferies LLC 520] [June 10, 2015 China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act We have examined the registration statement on Form S-3ASR (No. 333-204761) (“the Common Stock Preferred Stock Units Selling Stockholders Selling Stockholder Securities Securities Prospectus Prospectus Supplement Shares Underwriting Agreement We understand that 3,000,000 shares of Common Stock of which] [China Biologic Announces Pricing of Public Offering of Common Stock BEIJING, China – June 10, 2015 The Company intends to use the proceeds from the offering primarily for general corporate purposes. In addition, if appropriate opportunities arise in the future to acquire or invest in complementary businesses, products or technologies, the Company may use a portion of the net proceeds] []

[FOR RELEASE May 6, 2015 China Biologic Reports Financial Results for the First Quarter of 2015 1Q15 Total Sales Increases 25% to $70.4 Million 1Q15 Non-GAAP Net Income Increases 30.9% to $ 25.0 Million Raises FY15 Total Sales Forecast BEIJING, China – May 6, 2015 – First Quarter 2015 Financial Highlights · Total sales · Gross profit · Income from] []